CTRI/2014/08/004853已完成4 期
Efficacy and safety of febuxostat for retarding progression in chronic kidney disease with asymptomatic hyperuricemia: a double blind, randomized, placebo controlled trial.
Institute of Postgraduate Medical Education and Research Kolkata0 个研究点目标入组 93 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 93
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •(1)CKD stages 3 and 4 as determined by calculated creatinine clearances.
- •(2)Serum uric acid level more than 6 mg/dl
排除标准
- •1.requirement of medication (excluding diuretics) or conditions which may increase uric acid levels, such as disorders of primary uric acid metabolism. 2.autosomal dominant polycystic kidney disease
- •3. Patients with pregnancy, lactation
- •4. Symptomatic hyperuricemia or gout were also excluded from the trial.
研究者
相似试验
招募中
3 期
the effect of febuxostat in sepsisIRCT20230814059148N1Tabriz University of Medical Sciences40
已完成
3 期
A clinical trial to study the effect of two drugs, febuxostat and allopurinol in chronic management of hyperuricemia in patients with gout.CTRI/2009/091/000611Sun Pharmaceutical Industries Limited200
已完成
2 期
Dose-Response, Safety and Efficacy of Febuxostat in Subjects With GoutGoutNCT00174967Takeda153
招募中
2 期
The efficacy of fosaprepitant to the moderate emetic risk intravenous chemotherapyPatients who are not effective by two antiemetic drugs(5-HT3 antagonist and dexamethasone) for the moderate emetic risk intravenous chemotherapy(L-OHP, CPT-11, CBDCA)JPRN-UMIN000009311Division of Clinical Oncology, Tohoku University Hospital50
已完成
3 期
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With GoutGoutNCT02139046Takeda1,790